Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds

Name: Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
Published: 2020
License: Public Domain

Basilea Pharmaceutica · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

aspergillus covid

invasive fungal infections, apx001, apx001a, fosmanogepix, manogepix, aspergillus, aspergillosis, covid, covid19, mold, mould, pulmonary aspergillosis

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 1008645
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.